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Abstract
Background: The transcriptome complexity in an organism can be achieved by alternative splicing of precursor
messenger RNAs. It has been revealed that alternations in mRNA splicing play an important role in a number of
diseases including human cancers.
Methods: In this study, we exploited whole transcriptome sequencing data from five lung adenocarcinoma tissues
and their matched normal tissues to interrogate intron retention, a less studied alternative splicing form which has
profound structural and functional consequence by modifying open reading frame or inserting premature stop codons.
Results: Abundant intron retention events were found in both tumor and normal tissues, and 2,340 and 1,422 genes
only contain tumor-specific retentions and normal-specific retentions, respectively. Combined with gene expression
analysis, we showed that genes with tumor-specific retentions tend to be over-expressed in tumors, and the abundance
of intron retention within genes is negatively related with gene expression, indicating the action of nonsense mediated
decay. Further functional analysis demonstrated that genes with tumor-specific retentions include known lung cancer
driver genes and are found enriched in pathways important in carcinogenesis.
Conclusions: We hypothesize that intron retentions and consequent nonsense mediated decay may collectively
counteract the over-expression of genes promoting cancer development. Identification of genes with tumor-specific
retentions may also help develop targeted therapies.
Keywords: Intron retentions, RNA-Seq, Lung adenocarcinoma, Gene expression, Nonsense mediated decay
Background
As one of the leading causes of cancer-related mortality
in the world, lung cancer accounts for approximately 12
percent of all cancer incidences and 17.6 percent of
cancer deaths [1,2]. Of them, lung adenocarcinoma ac-
counts for more than 500,000 deaths per year worldwide
and is the most common subtype of non-small cell lung
cancer [3]. Although the underlying mechanism of
lung adenocarcinoma is still under investigation, studies
showed that recurrent mutations in the epidermal growth
factor receptor (EGFR) and the anaplastic lymphoma kin-
ase (ALK) fusions could change the efficacy of treatment
for patients with lung adenocarcinoma [4-8]. Genetic
modifications in other genes, including targeted muta-
tions in BRAF, AKT1, ERBB2 and PIK3CA, as well as
ROS1- and RET-involved fusions, may also affect cancer
therapy [9]. In addition, a recent study has found fre-
quent copy number changes in NKX2-1, TERT, PTEN,
MDM2, CCND1, and MYC in lung adenocarcinoma [3],
highlighting the role of various types of genetic alterna-
tions in carcinogenesis.
Alternative splicing in multiple-exon genes is prevalent
in eukaryotes and it is actively involved in development,
cell differentiation and disease. Approximately 90% of
multi-exon human genes have splicing variants in differ-
ent tissues and cell lines [10,11]. Intron retention, or the
maintenance of an intron in a mature mRNA transcript,
is a less common type of alternative splicing [12] and
can have large functional consequence by introducing
premature mutations to the mature transcript. Although
the impact of intron retentions has been less acknowl-
edged, a recent report suggests that intron retention is
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breast cancer subtypes [13], and the retention of intron
4 in the wild-type cholecystokinin type 2 (CCK2) recep-
tor shows elevated expression associated with increased
tumor growth in a few cancers [14].
The emergence of high-throughput sequencing tech-
nologies in the past few years has provided a new plat-
form to perform large-scale transcriptome profiling at
an affordable cost. Based on high-throughput sequen-
cing, RNA-Seq can precisely measure mRNA expression
and characterize gene isoforms [15,16], and is commonly
used to identify somatic mutations [17,18], differen-
tially expressed genes [19], fusion genes in tumor tis-
sue [20-22], and allele-specific expression [23,24]. Here
in the present study, we exploited the rich information
in RNA-seq data to investigate the potential role of in-
tron retentions in lung adenocarcinoma. Using tumor
and matched normal samples, we systematically identi-
fied genes with tumor-specific intron retentions. Fur-
ther investigation suggests a potential protective role of
intron retentions in carcinogenesis through the action
of nonsense mediated decay (NMD).
Methods
Transcriptome dataset
Transcriptome sequencing data from five lung adenocar-
cinoma and their paired adjacent normal tissue speci-
mens [17] were downloaded from European Nucleotide
Archive (ENA, http://www.ebi.ac.uk/ena/), using the ac-
cession number ERP001058. Reads from five patients
(LC1, LC5, LC10, LC11, and LC12) were used in this
study, and as described in the original study, all proto-
cols were approved by the Institutional Review Board of
Seoul National University Hospital (Approval # C-1111-
102-387) and Seoul St. Mary’s Hospital (Approval #
KC11TISI0678). 101-bp paired-end reads were generated
by Illumina Hiseq 2000 sequencer for each sample.
Exon-intron junction data
To extract exon-intron junction sequences, human exon
information was first downloaded from Ensembl database
(release 69) [25]. To assign exon-intron junction unam-
biguously, intersecting exons were excluded, resulting in
164,500 non-overlapping exons. Then exon-intron junc-
tions were then determined and 101-bp sequences were
extended in each direction for future mapping.
Identification of intron retentions
A strategy of two rounds of short read mapping was
adopted to identify retention reads. Bowtie2 [26] was first
used to align RNA-Seq reads to human cDNA sequences
(Ensembl release 69), with seed length as 20-bp. Un-
mapped reads were then extracted and mapped to exon-
intron junctions by Bowtie2, using the same parameter
above. Uniquely mapped reads with a minimum quality
score of 30 that cover a 20-bp region centered on the
exon-intron junction site and have at most two mis-
matches within this region were defined as retention reads.
A common tumor-specific retention (TSR) was defined
as an exon-intron junction that was supported by re-
tention reads from at least two tumor samples and no
retention read could be found in any normal sample.
Normal-specific retention (NSR) was similarly defined.
For each candidate TSR, we estimated its relative abun-
dance by recording the number of reads that covered
the junction position in the initial alignment, and reads
with insertion or deletions were excluded. Then for a
gene, the relative abundance of intron retentions was cal-
culated as:
Ri ¼
Xn
i¼1retention read of gene i
Xn
i¼1retention reads of gene i þ
Xn
i¼1reads mapped to cDNA for gene i
where Ri is the retention abundance for gene i.
Identification of differentially expressed genes (DEGs)
Gene expression was first calculated by using the RSEM
program [27], which effectively uses ambiguously-mapping
reads to estimate expression abundance. Next, EdgeR pack-
age was used to normalize the data by trimmed mean of M
values (TMM) and identify differentially expressed genes
[28]. Genes at low expression level (≤ 1t r a n s c r i p tp e rm i l -
lion reads, TPM) were excluded and DEGs were defined as
genes with a p-value< 0.05 after Benjamini-Hochberg
adjustment [29].
Identification of tumor-specific variants (TSVs)
Variants in tumor samples were first identified by
SAMtools [30] for each patient, and only variants sup-
ported by at least three reads with base quality ≥20 were
retained. Positions of those variants were then examined
in normal samples to make sure they were also covered
by reads from the corresponding normal samples and
they were not variable in normal samples.
Functional enrichment and pathway analysis
Gene ontology (GO) [31] information for query genes was
assigned using bioconductor (http://www.bioconductor.
org) package “org.Hs.eg.db”. Enrichment tests were per-
formed by assuming a hypergeometric distribution using
“topGO” package [32]. KEGG (Kyoto Encyclopedia of
Genes and Genomes) database [33] was used to retrieve
pathway annotation information, and Fisher’s exact test
was performed to evaluate the enrichment of a pathway.
Multiple test correction was conducted using Benjamini-
Hochberg method.
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Summary statistics of human intron retentions
The data used in this study were whole transcriptome
sequencing from tumor and adjacent normal tissues
of five patients with lung adenocarcinoma, containing
approximately 665 million short reads produced by
Illumina HiSeq2000 sequencer, about 67 million per sam-
ple (Additional file 1: Table S1). Using Bowtie 2 aligner,
about 647 million reads (~97%) can be mapped to human
cDNAs. The remaining 18 million unmapped reads were
further aligned to exon-intron junctions to identify po-
tential intron retention events. On average, 67,466 and
63,297 retention events were found in each tumor and
normal sample, respectively, with ~36,865 retentions in
common (Additional file 1: Table S1).
Genes with intron retentions
We next sought to identify genes with tumor-specific in-
tron retentions (TSRs). A TSR is an exon-intron junc-
tion that has been covered by retention reads in at least
two tumor samples but none of normal samples. As a
result, 4,099 TSRs were found by applying above criteria
(Table 1), compared to 2,437 normal-specific intron re-
tentions (NSRs). These tissue-specific intron retentions
were further mapped to genes, resulting in 2,983 genes
with TSRs and 1,991 genes with NSRs, respectively. Of
these genes, 500 have both TSRs and NSRs, suggesting
they may present different intron retention patterns in
tumor and normal samples. For the remaining 2,483
genes only containing TSRs (tumor-specific retention
genes, TSRGs, Additional file 2: Table S2), it is possible
that some genes may not be expressed in the normal
samples and thus lead to biased result. To exclude this
possibility, we assessed the expression pattern of TSRGs
and retained 2,340 genes that were expressed (>1 TPM)
in all tumors and normal controls under investigation.
Among them, 576 genes have more than one TSR. Com-
paratively, 1,422 expressed normal-specific retention genes
(NSRGs) were found, and 220 have more than one NSR
(Table 1).
Characterization of retained Introns
It has been proposed that in vertebrates, shorter introns
have a higher chance to be retained [34,35]. In order to
examine whether it is the case here, we compared the
size distribution of retained introns and non-retained
ones (Figure 1), and found that tumor-specific retained
introns are significantly shorter than non-retained in-
trons (1,293 bp versus 1,483 bp, median size, P-value =
4.8 ×10
−7, Wilconxon ranksum test). However, no such
pattern was found for normal-specific retained introns
(1,570 bp versus 1,483 bp, P-value=0.81). We also found
that the position of retained introns are not evenly dis-
tributed in the transcripts, and the last introns are most
likely to be retained in both tumor and normal samples,
but no obvious pattern can be found regarding the for-
ward order of introns (Figure 1).
Gene expression abundance and intron retention
abundance
Another question of interest is the relationship between
intron retentions and the expression level of genes. To
investigate it, we first used RSEM program to estimate
gene expression and EdgeR package in bioconductor to
identify genes that were differentially expressed be-
tween tumors and normal samples. In total, 6,060 dif-
ferentially expressed genes (DEGs) were identified with
a P-value<0.05 (after Benjamini-Hochberg correction).
Of them, 856 (~14%) genes were TSRGs (Figure 2),
which were significantly enriched (P-value=1. 2×1 0
−9,
Fisher’s exact test, FET). Additionally, when only consid-
ering 576 TSRGs with multiple retentions, we found a
more prominent overrepresentation of DEGs in this set
(261 DEGs, P-valu e=3 . 4×1 0
−13,F E T ) .I n t e r e s t i n g l y ,a
majority of TSRGs (659 of 856, 77%) are up-regulated
in tumor samples, which is again highly unexpected
(P-value<2.2×10
−16, binomial test). This skewness is
more substantial in TSRGs with multiple retentions
(239 of 261, 92%). We also studied the relationship
within tumor samples and a majority of genes (1474 of
2340, 63%) showed a positive correlation between the
intron retention count and expression level, which is
significantly deviated from the null expectation (50%,
P-value < 2.2 ×10
−16, binomial test) and is consistent
with previous observation [35].
One possible explanation for the over-representation
of intron retentions in tumors is the inhibition of non-
sense mediated decay (NMD), which degrades transcripts
with pre-mature codons [36] and is reported to be inhib-
ited in tumor microenvironment [37]. Therefore we in-
vestigated the expression pattern of 136 genes involved
in NMD process (Additional file 3: Table S3). Among
Table 1 Summary statistics for intron retentions in
normal and tumor samples
Normal Tumor
Group-specific retention (GSR)
a 2437 4099
Genes with GSR
b 1991 2983
Group-specific genes
c 1491 2483
Group-specific genes (TPM> 1)
d 1422 2340
Group-specific genes (TPM> 1 and GSR>1)
e 220 576
aIntron retentions only found in one group (TSR or NSR).
bGenes with TSR or NSR.
cGenes with TSR but not NSR or genes with NSR but not TSR.
dGroup-specific genes that are expressed more than one transcript per million
reads (TPM).
eGroup-specific genes that are expressed more than one transcript per million
reads (TPM) and have more than one GSR.
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nificantly down-regulated in tumors, implying NMD may
not be inhibited in lung adenocarcinoma and thus cannot
explain the large amount of intron retentions in tumors.
It should be noted that the observed correlation could
be simply explained by that retentions in over-expressed
genes are preferentially identified due to their abun-
dance. Therefore we estimated the intron retention
abundance in each TSRG. The mean and median abun-
dance of transcripts with intron retentions for a TSRG
in tumor samples are 18% and 5%, consistent with
previous observation that intron retentions comprise
a minor fraction of splicing forms [10]. Furthermore,
we found that up-regulated TSRGs have lower per-
centage of intron retentions compared with down-
regulated genes (4.5% versus 6.7%, median percentage,
P-value <2.2×10
−16, Wilconxon ranksum test). As tran-
scripts with premature stop codons tend to be degraded
by NMD [36], the low level of intron retentions in up-
regulated TSRGs and vice versa may suggest the presence
of NMD. To validate this, we categorized 2,340 com-
monly expressed TSRGs as genes with in-frame retention
(659) and genes with frame-shift retention (1681), and
compared their expression level as well as retention
Figure 1 Genomic features of retained introns. A. The size distribution of introns in different classes. The bin size is 500 bp, and introns larger
than 10,000 bp were included in one bin. The distribution showed tumor-specific retained introns are larger than other introns (see text). TSR:
tumor-specific retained introns; NSR: normal-specific retained introns; Other: non-retained introns. B. The percentage of retained introns in different
orders. Forward order is showed above the X-axis, and reverse order is showed under the X-axis. The histogram for introns after ten was truncated
to fit the plot. Tumor and normal samples are labeled by blue and darkred.
Zhang et al. BMC Medical Genomics 2014, 7:15 Page 4 of 9
http://www.biomedcentral.com/1755-8794/7/15abundance. Genes with in-frame retentions have higher
expression than those with frame-shift retentions (1581
versus 1356, mean TPM), but it was not statistically
significant (P-value = 0.4561, Wilconxon ranksum test).
The retention level in genes with in-frame retentions is
significantly higher compared with genes with frame-
shift retentions (6.3% versus 4.8%, median percentage,
P-value =4.0 ×10
−12, Wilconxon ranksum test), con-
firming NMD is active in tumor samples.
Functional analysis of TSRGs
To understand the potential functional relevance of
those 2,340 TSRGs, we further performed gene ontology
analysis. Of 19,520 expressed genes, TSRGs were found
to be enriched for 36 GO molecular function terms, in-
cluding binding terms and kinase activity terms, as well
as four cellular component terms (Additional file 4:
T a b l eS 4 ) .F o rt h es u b s e to fT S R G sw i t hm u l t i p l eT S R s ,s i x
biological process terms, 14 molecular function terms and
five cellular component terms were found overrepresented
(Table 2). Interestingly, several collagen-related terms were
found, such as GO0030199 (collagen fibril organization),
GO0005583 (fibrillar collagen) and GO0005581 (collagen).
As the most abundant proteins in the extracellular matrix,
collagen plays an essential role to prevent tumor cells me-
tastasizing to various sites throughout the body [38]. The
abundant intron retentions in collagen genes may facilitate
their degradation during tumor metastasis.
We also conducted pathway analysis for TSRGs and
five pathways were overrepresented (Table 2), including
the VEGF (vascular endothelial growth factor) signaling
pathway (hsa04370). This signal pathway contains sev-
eral key mediators of angiogenesis and lymphangiogen-
esis in tumor development [39], and is often found
highly expressed in tumors [40]. Enriched intron reten-
tions in these genes, again may activate the mRNA decay
mechanism to offset the over-expression.
Figure 2 Overrepresentation of genes with tumor-specific
retention (TSR) in differentially expressed genes (DEGs) between
tumor and normal samples. A: Venn diagram of DEG and genes
with TSR. B: pie chart of the expression pattern in tumor and normal
tissues for genes with TSR. A majority of DEGs are up-regulated in
tumors. Non-DEG: genes without differentially expression in tumor
and normal tissues; up-DEG: differentially expressed genes up-regulated
in tumor tissues; down-DEG: differentially expressed genes up-regulated
in normal tissues.
Table 2 Enriched gene ontology categories in genes with
multiple TSRs
Category
a Term Corrected
b Class
c
hsa05322 Systemic lupus erythematosus 4.99E-08 KEGG
GO:0005583 Fibrillar collagen 0.00163 GO:CC
hsa03010 Ribosome 1.74E-03 KEGG
GO:0005201 Extracellular matrix structural
constitu…
0.006651 GO:MF
GO:0007411 Axon guidance 0.009976 GO:BP
GO:0043062 Extracellular structure organization 0.009976 GO:BP
GO:0030199 Collagen fibril organization 0.009976 GO:BP
hsa00970 Aminoacyl-tRNA biosynthesis 1.03E-02 KEGG
hsa04370 VEGF signaling pathway 1.03E-02 KEGG
GO:0048407 Platelet-derived growth factor
binding
0.011402 GO:MF
GO:0044420 Extracellular matrix part 0.015466 GO:CC
GO:0005581 Collagen 0.015466 GO:CC
GO:0030198 Extracellular matrix organization 0.020783 GO:BP
GO:0006935 Chemotaxis 0.022168 GO:BP
GO:0042330 Taxis 0.022168 GO:BP
GO:0031256 Leading edge membrane 0.028215 GO:CC
hsa04510 Focal adhesion 3.64E-02 KEGG
GO:0005578 Proteinaceous extracellular matrix 0.047652 GO:CC
aCategories with more than 1000 genes were removed.
bFisher’s exact test after Benjamini-Hochberg correction.
cGO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes;
BP: biological process; MF: molecular function; CC: cellular component.
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One plausible reason for intron retentions is that muta-
tions occurred on the intron splicing sites which change
the splicing signal and thus result in an unspliced intron.
To explore the prevalence of splicing mutations in tu-
mors, we used SAMtools to identify single nucleotide
variants in tumors, and then filtered ones also variable
in the matched normal samples. In total, only 27 tumor-
specific variants were found to modify the splicing signal
(Additional file 5: Table S5). Considering the large num-
ber of tumor-specific intron retentions (4,099), it seems
that somatic mutations on splicing sites may have a neg-
ligible role in causing intron retentions. We also investi-
gated the expression level of several trans-acting splicing
activators, including Tra2 [41,42] and RNPS1 [43], but
none shows differential expression between tumors and
normal samples.
Intron retentions and tumor genes
By searching the COSMIC database (Catalogue of
Somatic Mutations in Cancer, http://cancer.sanger.ac.
uk/cancergenome/projects/cosmic/), we found TSRGs
include a substantial number of tumor genes, and some
are also represented in the Cancer Gene Census [44],
which catalogues genes with mutations that have been
causally implicated in cancer. Examples include EGFR
(epidermal growth factor receptor), KDR (kinase insert
domain receptor), ATM (ataxia telangiectasia mutated),
and ROS1 (c-ros oncogene 1, receptor tyrosine kinase).
Furthermore, three genes were among the top 20 most
frequently mutated genes in lung adenocarcinoma: EGFR
(34%), ATM (5%) and KDR (5%). TSRG list in this study
also targets other genes with a potential role in car-
cinogenesis, such as MUC16 (mucin 16, cell surface
associated), expression of which was found to correlate
with clinical outcome in adenocarcinomas [45], as well as
RUNX1 (runt-related transcription factor 1), which binds
to the core element of many enhancers and promoters
and may have various roles in tumors [46,47]. A close in-
vestigation further found reads across six exon-intron
junctions in MUC16, and the expression of MUC16 is
significantly elevated in tumors (p-value=3.98 ×10
−13
after Benjamini-Hochberg correction), but the abundance
of intron retention is 3.4%, smaller than 4.5%, the median
abundance of up-regulated TSRGs, implying the over-
expression of MUC16 in lung adenocarcinoma may be
related to the below average intron retention level. Fi-
nally, we also prioritized a list of TSRGs which contain
multiple frame-shift retentions and were significantly
over-expressed in tumor samples (Additional file 6:
Table S6). These genes include driver genes such as EGFR,
ROS1,a n dRUNX1, thus functional studies on them
should help understand the role of intron retentions in
lung tumor development.
Discussion
Recent large-scale efforts from Cancer Genome Atlas
Research Network have resulted in lung cancer candi-
date genes with somatic mutations and copy number al-
ternations [3,48]. However, variations at the mRNA level
in these are not fully explored, though the diversity and
functionality of tumor-specific transcripts have been
highlighted [10,49,50]. Several processes could result in
novel mRNA isoforms in tumors, including alterations
in promoter usage, exon skipping, and splicing signals,
which in consequence changes coding regions and the
resulting proteins [51-53]. Thus it is essential to under-
stand the contribution of cancer-related changes emer-
ging at the stage of transcription. The rapid development
of sequencing technology makes RNA-Seq a cost-
effective way to characterize transcriptome and is therefore
frequently used in biomedical studies. Here, we developed
a bioinformatics pipeline that explores RNA-Seq data to
identify intron retention events, a splicing form of less ap-
preciation but be also important in cancer study [13,54],
and further compared their spectrum between lung adeno-
carcinoma and matched normal tissues. A prevalence of
intron retentions was found in carcinoma samples, and
over-expressed TSRGs tend to have lower retention abun-
dance compared with under-expressed genes.
One important issue in identifying intron retentions is
to distinguish potential contaminations from genomic
DNAs or precursor mRNAs during the library preparation
process. In order to remove false positive calls caused by
contamination, we applied a simple and straightforward
filter that requires a candidate intron retention event to be
presented in at least two tumor samples and not in any
normal sample, or verse visa. If one sample is contami-
nated and contains false intron retentions, such retentions
are not expected to be found in other samples; if multiple
samples were contaminated, falsely called intron reten-
tions would be found in both tumor and normal samples,
which will also be removed by the filter. However, this fil-
ter also removes intron retentions occurred in individual
samples, thus the total number of TSRs or NSRs should
be even larger than reported here.
The nature of our bioinformatics pipeline determines
that it may have limited power in detecting intron reten-
tions in genes with low expression level, partially ac-
counting for the enrichment of intron retentions in
over-expressed genes. However, our pipeline also filtered
genes with very low expression, the abundance of intron
retentions in tumor samples thus cannot be simply ex-
plained by the expression bias. Additionally, when focus-
ing on genes with abundant expression, a reverse pattern
was demonstrated as the abundance of intron retention
is negatively correlated with gene expression, which is
likely the result of NMD. Since a substantial proportion
of cancer driver genes are over-expressed in tumors,
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may suggest a biological role to neutralize over-expression
in tumors.
With respect to the mechanism of somatic intron re-
tentions, the most intuitive explanation is that somatic
mutations occur at splicing sites and alternate the spli-
cing signal, therefore those splicing sites could not be
properly recognized. However, no enrichment of somatic
mutations was observed in this dataset (less than 1% of
TSRs have somatic mutations in the splicing sites). We
also interrogated the expression pattern of several spli-
cing activators, again, no obvious pattern was found.
Alternatively, some studies showed that intron reten-
tion pattern is different among various tissues [55-57],
suggesting other factors, such as cellular environment
may also function in promoting the process of intron
retention. In addition, the observation of smaller size
of retained intron in tumors compared to that in nor-
mal samples or non-retained introns is intriguing. Al-
though explanations have been proposed for short
retained introns [35], the difference between normal
and tumor samples remains unexplained. Future work
is therefore necessary to better understand the pattern
observed here.
Among genes with tumor-specific retentions, genes
with known driver functions in cancer were rediscovered,
including EGFR, ROS1, ATM and KDR. Additionally,
other growth factor genes were also found with retained
introns in tumor samples, such as PDGFRB (platelet-
derived growth factor receptor, beta polypeptide), TGFBI
(transforming growth factor, beta-induced), EGF (epidermal
growth factor), IGF2R (insulin-like growth factor 2 re-
ceptor), and ERBB2 (v-erb-b2 erythroblastic leukemia
viral oncogene homolog 2), which are also involved in
tumor evolution in various studies [58-62]. By detailed
investigation, we found intron retentions within these
genes all caused frame-shift changes, which tend to in-
voke NMD. It is well known that cancer driver genes,
such as EGFR, are over-expressed or activated by muta-
tions in tumors, further activating downstream pathways
associated with cell growth and survival. Therefore intron
retentions occurring in these over-expressed or highly
mutable driver genes could be protective for the patient
by triggering NMD, which in term reduces the expression
level or copies of mutable mRNAs. Future validation
studies and functional dissections, however, are still crit-
ical before we can draw the conclusion.
Conclusions
At the moment of this analysis, only a few studies focus
on systematically characterizing the global pattern and
contribution of intron retentions in tumorigenesis [63].
Results in this study suggest a potential protective role
of intron retentions in lung adenocarcinoma and may
benefit further biomarker development. It would also be
of interest to investigate the pattern of intron retentions
in other cancer types.
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